Cargando…

Respiratory Syncytial Virus Entry Inhibitors Targeting the F Protein

Human respiratory syncytial virus (RSV) is the main viral cause of respiratory tract infection in infants as well as some elderly and high-risk adults with chronic pulmonary disease and the severely immunocompromised. So far, no specific anti-RSV therapeutics or effective anti-RSV vaccines have been...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Zhiwu, Pan, Yanbin, Jiang, Shibo, Lu, Lu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2013
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3564118/ https://www.ncbi.nlm.nih.gov/pubmed/23325327 http://dx.doi.org/10.3390/v5010211

Ejemplares similares

Middle East respiratory syndrome coronavirus (MERS-CoV) entry inhibitors targeting spike protein
por: Xia, Shuai, et al.
Publicado: (2014)

Respiratory syncytial virus entry and how to block it
por: Battles, Michael B., et al.
Publicado: (2019)

Development of Protein- and Peptide-Based HIV Entry Inhibitors Targeting gp120 or gp41
por: Pu, Jing, et al.
Publicado: (2019)

Host Cell Entry of Respiratory Syncytial Virus Involves Macropinocytosis Followed by Proteolytic Activation of the F Protein
por: Krzyzaniak, Magdalena Anna, et al.
Publicado: (2013)

Intranasal Administration of Maleic Anhydride-Modified Human Serum Albumin for Pre-Exposure Prophylaxis of Respiratory Syncytial Virus Infection
por: Sun, Zhiwu, et al.
Publicado: (2015)

Approaches for Identification of HIV-1 Entry Inhibitors Targeting gp41 Pocket
por: Yu, Fei, et al.
Publicado: (2013)

Dichloro-Phenyl-Benzotriazoles: A New Selective Class of Human Respiratory Syncytial Virus Entry Inhibitors
por: Piras, Sandra, et al.
Publicado: (2019)

Protein- and Peptide-Based Virus Inactivators: Inactivating Viruses Before Their Entry Into Cells
por: Su, Xiaojie, et al.
Publicado: (2020)

The Quest for a Respiratory Syncytial Virus Vaccine for Older Adults: Thinking beyond the F Protein
por: Jenkins, Victoria A., et al.
Publicado: (2023)

Functional Features of the Respiratory Syncytial Virus G Protein
por: Anderson, Larry J., et al.
Publicado: (2021)

Discovery of a Novel Respiratory Syncytial Virus Replication Inhibitor
por: Wang, Li, et al.
Publicado: (2021)

A Pseudovirus-Based Entry Assay to Evaluate Neutralizing Activity against Respiratory Syncytial Virus
por: Hu, Longbo, et al.
Publicado: (2023)

A Short Double-Stapled Peptide Inhibits Respiratory Syncytial Virus Entry and Spreading
por: Gaillard, Vanessa, et al.
Publicado: (2017)

Respiratory syncytial virus is an “opportunistic” killer
por: Caballero, Mauricio T., et al.
Publicado: (2018)

Considerations for a Respiratory Syncytial Virus Vaccine Targeting an Elderly Population
por: Stephens, Laura M., et al.
Publicado: (2021)

Respiratory syncytial virus (RSV) entry is inhibited by serine protease inhibitor AEBSF when present during an early stage of infection
por: Van der Gucht, Winke, et al.
Publicado: (2017)

Sertraline Is an Effective SARS-CoV-2 Entry Inhibitor Targeting the Spike Protein
por: Chen, Yuliu, et al.
Publicado: (2022)

Immune Prophylaxis Targeting the Respiratory Syncytial Virus (RSV) G Protein
por: Bergeron, Harrison C., et al.
Publicado: (2023)

Respiratory Syncytial Virus
por: Fraire, Armando E., et al.
Publicado: (2013)

Respiratory syncytial virus
por: Ruuskanen, Olli, et al.
Publicado: (1993)

Respiratory syncytial virus
por: Munoz, Flor M., et al.
Publicado: (2020)

Influenza A Virus Entry Inhibitors Targeting the Hemagglutinin
por: Yang, Jie, et al.
Publicado: (2013)

Immunogenicity and safety of a respiratory syncytial virus fusion protein (RSV F) nanoparticle vaccine in older adults
por: Fries, Louis, et al.
Publicado: (2017)

A Novel CXCR4 Targeting Protein SDF-1/54 as an HIV-1 Entry Inhibitor
por: Tan, Suiyi, et al.
Publicado: (2019)

Late therapeutic intervention with a respiratory syncytial virus L‐protein polymerase inhibitor, PC786, on respiratory syncytial virus infection in human airway epithelium
por: Brookes, Daniel W, et al.
Publicado: (2018)

Respiratory syncytial virus infection: an innate perspective
por: Johansson, Cecilia
Publicado: (2016)

Respiratory syncytial virus: diagnosis, prevention and management
por: Barr, Rachael, et al.
Publicado: (2019)

Role of Respiratory Syncytial Virus in Pediatric Pneumonia
por: Bianchini, Sonia, et al.
Publicado: (2020)

Mucosal Immune Responses to Respiratory Syncytial Virus
por: Barnes, Megan V. C., et al.
Publicado: (2022)

Host Responses to Respiratory Syncytial Virus Infection
por: Agac, Ayse, et al.
Publicado: (2023)

Therapeutic efficacy of a respiratory syncytial virus fusion inhibitor
por: Roymans, Dirk, et al.
Publicado: (2017)

RAGE inhibits human respiratory syncytial virus syncytium formation by interfering with F-protein function
por: Tian, Jane, et al.
Publicado: (2013)

Respiratory syncytial virus: The virus, the disease and the immune response
por: Ogra, Pearay L.
Publicado: (2004)

Impact of Respiratory Syncytial Virus: The Nurse’s Perspective
por: Bracht, Marianne, et al.
Publicado: (2012)

The road to approved vaccines for respiratory syncytial virus
por: Ruckwardt, Tracy J.
Publicado: (2023)

Interleukin 1 and interleukin 1 inhibitor production by human macrophages exposed to influenza virus or respiratory syncytial virus. Respiratory syncytial virus is a potent inducer of inhibitor activity
Publicado: (1986)

Development of small-molecule viral inhibitors targeting various stages of the life cycle of emerging and re-emerging viruses
por: Wang, Xiaohuan, et al.
Publicado: (2017)

An Overview of Respiratory Syncytial Virus
por: Meng, Jia, et al.
Publicado: (2014)

Respiratory Syncytial Virus (RSV)
por: Walsh, Edward E., et al.
Publicado: (2015)

RIBAVIRIN AND RESPIRATORY SYNCYTIAL VIRUS
Publicado: (1986)

Cannot write session to /tmp/vufind_sessions/sess_3ee7g38ks48o3jtt2saphs286u